HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints. Phase III trials will now start for the colorectal indication of fruquintinib, even as development continues in two other indications.